Why the study?
Does extended thromboprophylaxis rivaroxaban reduce the composite endpoint of DVT, PE, and VTE-related death compared to in-hospital enoxaparin in hospitalized patients with heart failure and lower bleeding risk?
Does extended thromboprophylaxis rivaroxaban reduce the composite endpoint of DVT, PE, and VTE-related death compared to in-hospital enoxaparin in hospitalized patients with heart failure and lower bleeding risk?
Extended thromboprophylaxis with rivaroxaban significantly reduces VTE events without significantly increasing major bleeding in hospitalized heart failure patients at low bleeding risk.
Answers are grounded in this paper and cite their sources.
Extended rivaroxaban may reduce VTE in select HF patients; hypothesis-generating post hoc finding leaves confirmation to prospective trials.
This post hoc subgroup analysis examined efficacy and safety outcomes with extended thromboprophylaxis rivaroxaban compared with in-hospital enoxaparin in 2,078 patients from the MAGELLAN study who had a hospitalization for heart failure or a history of heart failure and a lower risk of bleeding. A significant 36% reduction in the composite endpoint of asymptomatic proximal deep vein thrombosis (DVT) in the lower extremity, symptomatic DVT in the lower extremity (proximal or distal), symptomatic nonfatal pulmonary embolism, and venous thromboembolism-related death was observed with rivaroxaban. Major bleeding was low in both groups and not significantly increased with rivaroxaban.
No takes yet. Share an insight, caveat, or question.
Spyropoulos et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: